This mTOR S2215Y mutation is located in the kinase domain.[28] The S2215Y mutation has been reported to result in constitutive activation of mTOR complex 1 (mTORC1) but not mTORC2 and to retain sensitivity to sirolimus.[29] Mutations in mTOR have not yet been reported in HCC.[7] FLT3 encodes a receptor tyrosine kinase. This evidence concerns the gene MTOR and hepatocellular carcinoma.